NASDAQ:MZE

Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug
····

Maze Therapeutics Heads for June With Wall Street Watching Kidney Drug

Maze Therapeutics shares slipped 1.2% to $26.05 in early Nasdaq trading Thursday, valuing the company near $1.4 billion. CEO Jason Coloma will present at Jefferies and Goldman Sachs healthcare conferences in June, where investors expect updates on the MZE829 kidney drug program. Maze reported $528 million in cash after an April stock sale and aims to start another Phase 2 study mid-year.
May 28, 2026

Stock Market Today

  • ASX Retail Stocks Face New Consumer Challenges
    May 28, 2026, 6:39 AM EDT. ASX-listed retail stocks are encountering a fresh consumer test amid changing market dynamics. Shifts in consumer behavior, inflation pressures, and economic uncertainty are impacting retail sector performance. Investors are closely watching how companies adapt to evolving demands and cost challenges. This environment underscores the importance of strategic agility for retailers to maintain market share and profitability. The test reflects broader economic factors influencing Australian retail stocks on the ASX.